Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis

Abstract

Background Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm with features of the myelodysplastic syndromes (MDSs) and myeloproliferative neoplasm presenting with peripheral blood monocytosis and an inherent risk for transformation to acute myeloid leukemia, while the abnormal DNA methylation plays a critical role in the pathogenesis of MDS, which is a disease of disordered differentiation. Recently, with the rapid development of molecular biology, hypomethylating agents (HMAs) for the treatment of MDS has gradually become a research focus. The objective of this study was to evaluate the benefits and risks of HMAs for patients with CMML.
Materials and Methods PubMed, Embase, the Cochrane Library, and three Chinese databases were searched for studies published before November 2020 that used HMAs in CMML.
Results The pooled objective response rate (ORR), complete response (CR), and partial response (PR) were 50.0, 21.0, and 2.0%, respectively. The proportion of patients with minor response (MR) was significantly higher for decitabine (DAC) than for azacitidine (AZA). There was no significant difference in hematologic improvement, ORR, CR, and PR rates between the DAC and AZA groups. Hematological toxicity included neutropenia grade 3/4 (14.0%), anemia grade 3/4 (17.0%), and thrombocytopenia grade 3/4 (22.0%).
Conclusion This study showed that HMAs were effective and safe in the treatment of CMML, but large multicenter study would be needed to confirm the efficacy of HMAs for the treatment of CMML with different risk level and genetic abnormality, to support individualization treatment theoretically.

Keywords

chronic myelomonocytic leukemia / hypomethylating agents / meta-analysis / myelodysplastic syndromes / single-arm / azacitidine / decitabine

References

[1] Itzykson R, Fenaux P, Solary E.Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?. Best Pract Res Clin Haematol 2013; 26(04): 387-400

[2] Arber DA, Orazi A, Hasserjian R.et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20): 2391-2405

[3] Eissa H, Gooley TA, Sorror ML.et al.Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 2011; 17(06): 908-915

[4] Elliott MA, Tefferi A, Hogan WJ.et al.Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006; 37(11): 1003-1008

[5] Park S, Labopin M, Yakoub-Agha I.et al.Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol 2013; 90(05): 355-364

[6] Edlin R, Connock M, Tubeuf S.et al.Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Health Technol Assess 2010; 14(01): 69-74

[7] Steensma DP.Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?. Best Pract Res Clin Haematol 2012; 25(04): 443-451

[8] Steensma DP.Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J 2018; 8(05): 47

[9] Mora E, Sanz GF.Current management of patients with chronic myelomonocytic leukemia. Curr Opin Oncol 2018; 30(06): 409-417

[10] Onida F.Models of prognostication in chronic myelomonocytic leukemia. Curr Hematol Malig Rep 2017; 12(06): 513-521

[11] Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J.Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003; 73(09): 712-716

[12] Cheson BD, Greenberg PL, Bennett JM.et al.Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108(02): 419-425

[13] Santini V, Allione B, Zini G.et al.A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia 2018; 32(02): 413-418

[14] Drummond MW, Pocock C, Boissinot M.et al.A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia 2014; 28(07): 1570-1572

[15] Wijermans PW, Rüter B, Baer MR, Slack JL, Saba HI, Lübbert M.Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008; 32(04): 587-591

[16] Tantravahi SK, Szankasi P, Khorashad JS.et al.A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. Leuk Lymphoma 2016; 57(10): 2441-2444

[17] Alfonso A, Montalban-Bravo G, Takahashi K.et al.Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol 2017; 92(07): 599-606

[18] Coston T, Pophali P, Vallapureddy R.et al.Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol 2019; 94(07): 767-779

[19] Diamantopoulos PT, Kotsianidis I, Symeonidis A.et al; Hellenic MDS study group. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. Leuk Lymphoma 2019; 60(07): 1721-1730

[20] Helbig G, Chromik K, Woźniczka K.et al.Real life data on efficacy and safety of azacitidine therapy for myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia. Pathol Oncol Res 2019; 25(03): 1175-1180

[21] Pleyer L, Germing U, Sperr WR.et al.Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res 2014; 38(04): 475-483

[22] Tendas A, Cupelli L, Siniscalchi A.et al.Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach. Mediterr J Hematol Infect Dis 2014; 6(01): e2014020

[23] Fianchi L, Criscuolo M, Breccia M.et al.High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma 2013; 54(03): 658-661

[24] Wong E, Seymour JF, Kenealy M, Westerman D, Herbert K, Dickinson M.Treatment of chronic myelomonocytic leukemia with azacitidine. Leuk Lymphoma 2013; 54(04): 878-880

[25] Thorpe M, Montalvão A, Pierdomenico F, Moita F, Almeida A.Treatment of chronic myelomonocytic leukemia with 5-azacitidine: a case series and literature review. Leuk Res 2012; 36(08): 1071-1073

[26] Costa R, Abdulhaq H, Haq B.et al.Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011; 117(12): 2690-2696

[27] Aribi A, Borthakur G, Ravandi F.et al.Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007; 109(04): 713-717

[28] 282013 CARE Checklist.[Internet]. Available at: https://www.care-statement.org/checklist

[29] Silverman LR, Demakos EP, Peterson BL.et al.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20(10): 2429-2440

[30] Kantarjian H, Issa JP, Rosenfeld CS.et al.Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106(08): 1794-1803

[31] Shapiro RM, Lazo-Langner A.Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. BMC Hematol 2018; 18: 3

[32] Yang B, Yu R, Cai L.et al.A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis. Ann Hematol 2017; 96(11): 1811-1823

[33] Rius M, Stresemann C, Keller D.et al.Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther 2009; 8(01): 225-231

[34] Hollenbach PW, Nguyen AN, Brady H.et al.A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010; 5(02): e9001

[35] Gao C, Wang J, Li Y.et al.Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: a systematic review and meta-analysis. Medicine (Baltimore) 2018; 97(34): e11860

RIGHTS & PERMISSIONS

2022 Global Medical Genetics